Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
Published: Feb 05, 2013
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTC:ORMPD) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that Nadav Kidron, Chief Executive Officer & Director, will present at RetailInvestorConferences.com.
DATE: February 7, 2013
TIME: 9:15 AM EST
LINK: www.retailinvestorconferences.com > red "register / watch event now" button
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching FDA-approved Phase 2 clinical trials, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 1b/2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC)PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.
SOURCE Oramed Pharmaceuticals Inc.